Litcius/Paper detail

The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients

Esther Saiag, Ayelet Grupper, Irit Avivi, Ori Elkayam, Ron Ram, Yair Herishanu, Yaël C. Cohen, Chava Perry, Victoria Furer, Helena Katchman, Liane Rabinowich, Merav Ben‐Yehoyada, Tami Halperin, Roni Baruch, Hanoch Goldshmidt, David Hagin, Ronen Ben‐Ami, Eli Sprecher, David Bomze

2022Clinical Microbiology and Infection35 citationsDOIOpen Access PDF

Topics & Concepts

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakMedicineVirologyAntibodyAntibody responseImmunologyInternal medicineInfectious disease (medical specialty)OutbreakDiseaseSARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesHeparin-Induced Thrombocytopenia and Thrombosis
The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients | Litcius